


Upto **86%** of exacerbations in COPD are associated with increased **breathlessness**<sup>1</sup>



When **breathlessness** strikes,  
give your patients **quick relief**



Rx In COPD Management

# duolin



**RAPID RELIEF**  
FROM SYMPTOMS\*

inhaler Levosalbutamol (50mcg) + Ipratropium (20mcg)  
rotacaps Levosalbutamol (100mcg) + Ipratropium (40mcg)  
forte Levosalbutamol (100mcg) + Ipratropium (80mcg)



Don't wait,  
Act in  
**48**  
Seconds



Rx In COPD Management

# duolin




**RAPID RELIEF**  
FROM SYMPTOMS\*

inhaler Levosalbutamol (50mcg) + Ipratropium (20mcg)

rotacaps Levosalbutamol (100mcg) + Ipratropium (40mcg)

forte Levosalbutamol (100mcg) + Ipratropium (80mcg)

Combination of SABA + SAMA showed improvement in Shortness of Breath v/s Monotherapy%





Rx In COPD Management

duolin



inhaler Levosalbutamol (50mcg) + Ipratropium (20mcg)

rotacaps Levosalbutamol (100mcg) + Ipratropium (40mcg)

forte Levosalbutamol (100mcg) + Ipratropium (80mcg)

Available in complete range



Images/ Characters shown here is for reference purpose only. Ref.:1. Clin. Drug Invest. 14, 400-404 (1997). COPD: Chronic obstructive pulmonary disease \*Br J Anaesth 2009; 103 (Suppl.1): i57-i65 #onset of action of Salbutamol \$ IQVIA MAT April'25

For prescribing information refer : <https://www.ciplamed.com/product-index/duolin-inhaler?product-speciality=All>

Duolin Forte Rotacaps <https://www.ciplamed.com/product-index/duolin-forte-rotacaps?product-speciality=All>

Duolin Rotacaps: Dosage, Uses, Contraindications & Prescribing Info | Ciplamed <https://www.ciplamed.com/product-index/duolin-rotacaps>

To report any adverse events/special situation, email at [drugsafety@cipla.com](mailto:drugsafety@cipla.com) or report to Cipla Ltd. on 1800 267 7779 as soon as possible.

Additional Information Available on request.

Disclaimer - This detailer is meant only for the use of Cipla and its authorized representatives for communication with the Registered Medical Practitioner. Copying, circulation or reproduction of this is strictly prohibited. Any unauthorized person having possession of this document should discard the same or inform/notify/return to Cipla Ltd. The inclusion or exclusion of any product does not mean that the publisher or author either recommends or rejects its use either generally or in any particular field or fields. Prescription of the drug is the prerogative of Registered Medical Practitioner at his/her sole discretion.



For any further information, please contact: Cipla Ltd.

Regd. Office: Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India. Website: [www.cipla.com](http://www.cipla.com)